Cartesian Therapeutics Inc RNAC.OQ RNAC.O is expected to show a fall in quarterly revenue when it reports results on March 5 (estimated) for the period ending December 31 2024
The Frederick Maryland-based company is expected to report a 98.7% decrease in revenue to $103.75 thousand from $8.27 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Cartesian Therapeutics Inc is for a loss of 80 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Cartesian Therapeutics Inc is $41.00, above its last closing price of $18.84.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.78 | -0.79 | -1.13 | Missed | -42.7 |
Jun. 30 2024 | -0.91 | -1.07 | 0.54 | Beat | 150.6 |
Mar. 31 2024 | -0.80 | -0.88 | -10.50 | Missed | -1,086.4 |
Dec. 31 2023 | -0.60 | -1.05 | -2.10 | Missed | -100 |
Sep. 30 2023 | -1.34 | -1.75 | -1.80 | Missed | -2.9 |
Jun. 30 2023 | -2.31 | -2.40 | -2.10 | Beat | 12.5 |
Mar. 31 2023 | -2.62 | -2.61 | -4.20 | Missed | -60.7 |
Dec. 31 2022 | -2.47 | -2.19 | 1.20 | Beat | 154.9 |
This summary was machine generated March 3 at 13:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。